Loratin

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Loratin

Quick Facts

Property Description
Active ingredient Loratadine (INN)
Form Tablet, Syrup, Rapidly-disintegrating tablet
Pharmacological class Second-generation Antihistamine (H₁-receptor antagonist)
Common use Systemic relief of histamine-mediated allergic symptoms
Origin Synthetic organic compound

Defining Loratin: The Identity and Pharmacological Class

Loratin is a brand name preparation containing the active ingredient Loratadine (INN), a synthetic compound chemically classified as a tricyclic piperidine derivative. The medication is an established second-generation antihistamine that functions as a selective H₁-receptor antagonist. As a non-sedating antihistamine in typical use, it is distinguished from older compounds in its class.

Loratadine achieves its action by competitively inhibiting histamine at peripheral H₁-receptor sites, thereby blocking the effects of histamine—the natural chemical mediator released in the body during an allergic response. The compound’s sustained antagonism provides effective, long-lasting relief from the general discomfort associated with hypersensitivity. This targeted action is the basis of its therapeutic value.

Forms, Composition, and General Therapeutic Purpose

Loratadine is manufactured as a systemic therapeutic agent intended for oral administration, available in common pharmaceutical preparation forms such as the standard tablet, the oral syrup (solution), and specialized dissolving tablets. This flexibility in formulation ensures the medication can accommodate various patient groups. As a long-acting compound, Loratadine, which is typically used as a single active ingredient product, is designed to provide sustained control over the body’s reaction to allergens.

The general therapeutic purpose of this medication is the sustained control of the body’s hypersensitivity response. By effectively interrupting the histamine cascade throughout the body for an extended period, Loratin helps to mitigate the physical signs that result from these histamine-mediated allergic reactions.

Regulatory References

  1. Loratadine - StatPearls - NCBI Bookshelf
  2. Loratadine: MedlinePlus Drug Information

What side effects are possible with Loratin?

Loratin: Possible Side Effects and Safety Information

Loratin's official safety profile describes adverse reactions identified in clinical trials and those reported post-marketing, categorized by frequency and the body system affected.


Adverse Reaction Scope

Component Description
Frequency Classification Common reactions in adults and adolescents include Headache, Somnolence (drowsiness), Increased appetite, and Insomnia. In children aged 2–12 years, Common reactions reported in excess of placebo were Headache, Nervousness, and Fatigue.
System-Organ Classes Adverse reactions have been reported across several systems, including Nervous system disorders (e.g., dizziness, convulsion), Cardiac disorders (e.g., tachycardia, palpitation), Gastrointestinal disorders (e.g., dry mouth, gastritis), and Hepatobiliary disorders (e.g., abnormal hepatic function).
Serious Adverse Reactions Reactions identified as Very Rare based on post-marketing surveillance include severe Hypersensitivity reactions (such as Angioedema and Anaphylaxis), Convulsion, and serious Abnormal hepatic function (including Jaundice, Hepatitis, and Hepatic necrosis).

Population-Specific Safety Notes

Official labeling contains specific notes for individuals with pre-existing conditions. For patients with Severe Hepatic Impairment or Renal Impairment, the elimination of Loratadine may be altered, resulting in increased plasma concentrations. The safety and effectiveness of the medicine have not been established for the pediatric population under 2 years of age.


Safety-Related Restrictions

Antihistamines, including Loratadine, may diminish or prevent positive reactions to Skin Allergy Tests; therefore, temporary discontinuation of the medicine before such tests is advised in the official regulatory documentation. Furthermore, while the medicine is generally non-sedating, the regulatory text notes that the potential for Somnolence, particularly if the recommended dose is exceeded, may affect the ability to drive or operate machinery. Concomitant use with known inhibitors of CYP3A4 or CYP2D6 enzymes may lead to elevated plasma concentrations of Loratadine.


The official safety profile systematically structures the medicine's risk information by distinguishing between expected, Common adverse reactions and Very Rare but serious systemic events. This framework ensures that both frequent reactions and critical, rare risks, along with specific constraints for patients with Hepatic or Renal impairment, are formally documented.

Overdose and Emergency Response

Loratin Overdose and When to Seek Help

The official regulatory documentation identifies specific clinical manifestations associated with Loratadine overdosage. The most frequently documented clinical signs are somnolence (drowsiness), headache, and tachycardia (rapid heartbeat). An increased occurrence of anticholinergic symptoms is also documented as a physiological effect stemming from overexposure.

Regulatory-Mandated Emergency Actions

Overdosage is a serious state that requires immediate medical attention. Regulators mandate that patients seek immediate medical help and contact a Poison Control Center right away if an overdosage is suspected, regardless of the apparent symptoms. Treatment for this scenario must be started immediately by healthcare professionals.

Official Management and Monitoring

The official management approach is defined as symptomatic and supportive measures. Procedural steps that may be considered to manage the overexposure include the use of activated charcoal as a slurry with water, and gastric lavage. Regulatory information confirms that the drug is not removed by haemodialysis as a means of clearance. Following any initial emergency treatment, the patient requires continued medical monitoring as dictated by official prescribing information. This structured regulatory guidance defines the specific signs and mandates urgent intervention.

Therapeutic Uses of Loratin

What Loratin Treats: Main Uses and Benefits

Loratin is commonly used for managing symptoms related to inflammatory or irritative states driven by allergic responses. Its therapeutic role is focused on offering symptomatic relief across key domains of allergic discomfort.

The medication is relevant for easing challenging symptoms associated with specific conditions, including seasonal allergic rhinitis (hay fever), perennial allergic rhinitis, and chronic idiopathic urticaria (hives). Loratin is applied across domains where additional symptomatic support is needed to address symptom clusters that may become intense or disruptive. This provides support that helps ease the overall symptom burden and may help patients cope more steadily with difficult episodes.

Quick Fact: Support for Symptomatic Relief

Therapeutic Domain Symptom Clusters Addressed Patient Benefit Focus
Allergic Rhinitis Sneezing, runny nose, itchy eyes/throat Assists with maintaining functional stability.
Dermatological Pruritus, hives (urticaria), wheals Contributes to improved comfort during symptomatic periods.

Therapeutic Applications

Managing Allergic Manifestations

Loratin is commonly used to help with the intensity of nasal, ocular, and skin symptoms. This includes managing sneezing, profuse runny nose (rhinorrhea), and concurrent itching of the nose, throat, and eyes. For dermatological discomfort, it is relevant for easing the intensity of skin itching and the visible symptoms of wheals or rash. Offering supportive relief helps ease the overall symptom burden and may assist with maintaining functional stability during periods of heightened symptoms.

“It is commonly used when short-term symptomatic assistance is needed and maintaining alertness for daily routine activities is a priority.”

Eligibility and Restrictions for Use

This section outlines the official eligibility and non-eligibility requirements for Loratadine, strictly based on regulatory documentation.

Contraindications and Exclusionary Groups

Category Regulatory Status
Hypersensitivity Contraindicated: Use is prohibited in patients with a known allergy to loratadine or any of the product's inactive ingredients.
Excipient-Based Restriction Certain formulations containing aspartame are excluded for patients with Phenylketonuria (PKU).

Age and Special Population Eligibility

Population Official Eligibility Status
Adults (12+ years) Eligible for standard use.
Children 2 to 12 years Eligible with age-appropriate dosing/formulation.
Children under 2 years Safety and efficacy are not established; use is not recommended or requires explicit medical determination.
Pregnancy Use is not recommended; it is advised to avoid use as safe use during pregnancy has not been definitively established.
Lactation Use is not recommended as Loratadine is excreted in breast milk.

Conditional Use Requirements

Patients with severe hepatic impairment (severe liver disease) or severe renal impairment (kidney disease with GFR <30 mL/min) are generally eligible, but require a dose adjustment (e.g., administering the dose every other day) due to reduced drug clearance. Use must also be discontinued for at least 48 hours prior to any allergy skin testing.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Loratin (Loratadine) primarily exhibits pharmacokinetic interactions related to its hepatic metabolism. The drug is processed mainly by the Cytochrome P450 3A4 (CYP3A4) enzyme, and to a lesser extent by CYP2D6. Co-administration with certain inhibitors of these enzymes substantially increases the plasma concentration (AUC) of Loratadine and its active metabolite, descarboethoxyloratadine.

Documented Exposure-Modifying Substances

Category Specific Interacting Medicines Interaction Outcome (Regulatory Description)
CYP Enzyme Inhibitors Ketoconazole, Erythromycin, Cimetidine Substantially increase plasma concentrations (AUC) of Loratadine.
Food Food Increases systemic exposure (AUC) by approximately 48% and delays time to peak concentration (Tmax).
Alcohol Alcohol No potentiating effects on psychomotor performance were documented in official studies.

Administration Timing and Population Considerations

The regulatory profile includes a mandatory timing rule: the drug must be discontinued at least 48 hours before any dermal reactivity index (skin) tests to prevent interference with diagnostic results. Furthermore, patients with severe liver impairment or renal impairment (creatinine clearance less than 30 mL/min) are noted to be at greater risk for drug and metabolite accumulation due to reduced clearance.

Mechanism of Action

Blocking the H1 Histamine Receptor

Loratin functions as a selective antagonist (blocker) by binding specifically to the H1 histamine receptors located on cell surfaces throughout the body. This interaction prevents the body’s naturally released chemical, histamine, from binding and initiating a signaling cascade. The mechanism focuses on inhibiting the receptor's signaling capability rather than altering the amount of histamine produced.


Inhibiting Peripheral Tissue Signaling

Loratin's mechanism is concentrated on influencing peripheral systems—specifically the blood vessels, smooth muscle, and nerves outside of the central nervous system—where H1 receptors are prevalent. By modifying these early molecular steps, the drug supports the regulation of processes driven by distinct signaling patterns at the tissue level.


Modulating Capillary Fluid Dynamics

The mechanistic consequence of blocking H1 receptors is the inhibition of the signal that causes capillary walls to widen and increase permeability. This physiological adjustment contributes to the stabilization of fluid balance and reduces plasma leakage into surrounding tissues, which shapes the drug's overall effect profile.

Dosage and Administration Information

How to use Loratin

Loratin (loratadine) is a long-acting antihistamine administered exclusively by the oral route as tablets, syrup, or rapidly-disintegrating tablets. It is typically used in a single daily dose to achieve continuous 24-hour systemic activity.


Official Dosing and Administration Schedules

The standard dose for adults and children aged 6 years and older is 10 mg once daily, with a maximum limit of 10 mg in a 24-hour period. Dosing for children aged 2 to 5 years is 5 mg once daily. The medicine may be taken without regard to mealtime.

Age Group or Condition Dosing Regimen (Maximum Daily Dose) Preparation Note
Adults and children aged 6 years and older 10 mg once daily Take with or without food.
Children 2 to 5 years 5 mg once daily Typically administered using the oral syrup or a chewable form.
Severe Hepatic Impairment 10 mg every other day Reduced dose to account for potentially reduced clearance.

Procedural and Administration Rules

Special Procedural Condition: The administration of loratadine is discontinued at least 48 hours prior to any scheduled diagnostic skin testing. This is a procedural step to ensure the integrity of the test results. No dose adjustment is required for elderly patients or those with renal impairment.

This structured dosing protocol ensures the consistent application of the once-daily oral schedule, with specific modifications for children under 6 and patients with severe liver impairment.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Loratin (Loratadine)

The research base for Loratin, which contains the active ingredient Loratadine, aligns with documentation submitted to regulatory authorities and a range of published scientific literature. The research primarily consists of Randomized Controlled Trials (RCTs) and systematic reviews, exploring how the medicine is compared to an inactive substance (placebo) or to other established treatments.


Evidence for Use in Allergic Rhinitis

Research exploring allergic rhinitis (seasonal and perennial forms, commonly known as hay fever) has utilized numerous studies. These studies examined populations including adults, adolescents, and children (starting from two years of age). Outcomes measured focused on symptoms linked to inflammatory or irritative states, such as the severity of sneezing, runny nose, nasal itching, and ocular (eye) symptoms.

Findings described patterns where symptom scores were reported as different between the groups that received Loratadine and those receiving placebo. The studies observed different reported levels of somnolence when compared with older, first-generation antihistamines. A key limitation noted is that the studies did not consistently monitor significant measurable changes in the symptom of nasal congestion or stuffiness compared to the data for other symptoms like sneezing and itching.


Evidence for Use in Chronic Idiopathic Urticaria (Hives)

Research has been applied in studies examining Chronic Idiopathic Urticaria (CIU), or chronic hives. The studies primarily involved placebo-controlled trials that monitored outcomes in adults and adolescents with CIU. Outcomes monitored included the severity of pruritus (itching) and the number and size of wheals (hives). Trial data described patterns where measured skin symptoms were reported as different compared to the placebo group. This pattern of findings has contributed to its inclusion in established therapeutic guidelines for the management of CIU.


What is Still Uncertain About Loratin

The most notable limitation in the research is the finding that data show patterns related to limited measurable changes in nasal congestion. Furthermore, comparative evidence is lacking for certain groups, and data for other complex subgroups, such as those with significant coexisting health issues, remain insufficient to draw broad conclusions.

Key Studies & References

  1. Loratadine: Mechanism of action, pharmacokinetics, and clinical efficacy in allergic rhinitis and chronic urticaria (StatPearls)

Frequently Asked Questions (FAQ)

Common questions about Loratin (FAQ)

Q: How long does it usually take to notice effects after starting Loratin?

Official information indicates that the first effects of the medicine can be noticed within one to three hours after taking a single oral dose. The effect typically reaches its reported peak concentration within 8 to 12 hours after the dose.

Q: Are there common household items or supplements that might interact with Loratin?

Official studies did not find that Loratin increased the effects of alcohol on coordination or performance. However, co-administration with other substances known to inhibit the liver's CYP3A4 or CYP2D6 enzymes may result in increased exposure to loratadine in the body.

Q: Why do some people say Loratin stops working after a while?

While some user reports suggest a loss of effect over time, a regulatory-referenced study specifically investigated this over a 12-week period. The study concluded that there was no evidence of tolerance (or subsensitivity) developing during that time.

Q: What is the difference between Loratin and over-the-counter options for the same condition?

Loratin contains the active ingredient loratadine, which is officially categorized as a second-generation antihistamine. This class of medicine is generally considered non-sedating at recommended doses, a property that distinguishes it from older, first-generation antihistamine compounds.

Q: Can taking Loratin make me gain weight?

Official safety profiles for Loratin list increased appetite as one of the common adverse reactions reported in clinical trials for adults. However, weight gain itself is not explicitly identified as an adverse reaction in the official US product labeling.

Q: Is Loratin likely to interact with herbal supplements like St. John's Wort?

Regulatory-referenced guidance indicates that St. John's Wort may interact with Loratin. This is because the herb may induce (or speed up the activity of) the enzymes that metabolize the drug, which may affect the overall activity of Loratin.

Q: Does Loratin contain common allergens like gluten or lactose?

Many tablet formulations of Loratadine contain lactose monohydrate as an inactive ingredient. For individuals with Phenylketonuria (PKU), certain formulations containing aspartame are excluded from use.

Q: Are generic versions of Loratin equivalent to the brand name version?

Generic products are authorized through a bioequivalence study by regulatory agencies. This study demonstrates that the generic version achieves equivalent levels of the active substance (loratadine) in the body as the original brand product.

Q: What are the official restrictions regarding using Loratin before surgery?

Official documentation specifically requires that Loratin administration must be discontinued at least 48 hours before any scheduled diagnostic skin testing. This procedural step is required to ensure accurate diagnostic test results.

Q: Do official sources discuss potential long-term benefits beyond the treatment period for Loratin?

Official regulatory documentation focuses primarily on the benefits of the medication during the active treatment period. Information concerning residual or sustained benefits after a person stops taking the drug is not routinely included in the product label.

Q: Does Loratin have different formulations (liquid, tablet, extended-release)?

Loratin is available in several forms for oral administration, including a standard tablet, an oral syrup (solution), and rapidly-disintegrating tablets. An extended-release tablet formulation is also available when Loratadine is combined with pseudoephedrine.

Q: What happens if someone forgets to take Loratin for a day?

Official patient information generally describes taking the missed dose as soon as it is remembered, unless it is nearly time for the next dose. It is further stated that patients should not take a double dose to make up for a missed one.

Q: How long does Loratin stay in the system after stopping use?

Regulatory documents describe the elimination half-life of Loratadine as approximately 8.4 hours in healthy adults. Its major active compound, descarboethoxyloratadine, has a longer half-life, reported at around 28 hours.

Q: What kind of studies led to Loratin's approval?

The regulatory approval process relied on a review of clinical data, primarily including Randomized Controlled Trials (RCTs). These studies established the drug's safety and efficacy when compared to an inactive substance (placebo) for its approved uses.

Q: Are there documented differences in how Loratin affects children versus adults?

Yes, the common adverse reactions reported in clinical trials differed between the populations. For adults, common reactions included headache and drowsiness, while for children aged 2–12 years, common reactions included headache, nervousness, and fatigue.

Q: Do older adults react differently to Loratin than younger adults?

Official administration guidance notes that no dose adjustment is typically required for elderly patients. Loratadine is often selected for this population because of its established lower potential for causing drowsiness compared to older types of antihistamines.

Q: What if I experience unusual dreams or sleep disturbances while taking Loratin?

Official safety profiles report Insomnia (difficulty sleeping) as a common adverse reaction in adults and Nervousness as a common reaction in children. These reports fall under the Nervous System category of side effects.

Q: What should I do if a minor side effect of Loratin seems concerning?

Official patient information notes that for mild side effects that are bothersome or do not resolve, patients may contact their doctor or pharmacist.

Q: Do studies suggest Loratin is more effective at night or in the morning?

Official regulatory dosing recommends that the medication be taken once daily, and it can be taken without regard to food consumption. This schedule is designed to provide continuous 24-hour relief from symptoms.

Q: Why are there different brand names for the same medicine, Loratin?

The active ingredient is loratadine, an international nonproprietary name. This substance is manufactured and sold under many different brand names globally, often differentiating the original developer product from subsequent generic versions.

Q: What information is usually provided to patients about stopping Loratin?

The main requirement provided in official documentation is to stop the drug at least 48 hours prior to any skin allergy testing. No general information about withdrawal or tapering is routinely included in the patient label for non-allergic test discontinuation.

Q: What are the financial costs of Loratin usually based on?

The historical cost of the brand-name product was influenced by its patented status. However, the subsequent regulatory approval and introduction of generic products have been the most significant factor impacting the current market price and cost structure.

Q: Why are some people concerned about the 'active ingredient' in Loratin?

Regulatory bodies have investigated specific safety signals over time, such as a possible connection to a congenital anomaly in early pregnancy. Regulatory bodies have also initiated investigations or communications regarding the bioequivalence of certain generic versions, ensuring the medication meets standards.

Q: Is Loratin linked to any specific mental health side effects in regulatory warnings?

Adverse reactions are reported across the Nervous System category, which includes symptoms like Nervousness (common in children), dizziness, and convulsion (reported as very rare). These reports cover effects on the nervous system.

Q: How much of the research on Loratin has been done outside the US?

The drug is authorized globally by multiple international regulatory bodies, such as the European Medicines Agency (EMA). Their review process evaluates comprehensive data from clinical trials and patient registries originating from multiple countries around the world.

Q: Is there scientific evidence supporting the use of Loratin for conditions other than its main approved use?

The main approved uses are allergic rhinitis and chronic idiopathic urticaria. Current research registered in clinical trial databases is exploring its use in combination with other medicines for the symptomatic relief of conditions like the common cold.

Q: Can I crush or split Loratin tablets if they are hard to swallow?

Loratin is manufactured in multiple forms for ease of use, including a syrup and rapidly-disintegrating tablets. While some administration guidelines suggest crushing tablets under certain conditions, this is not a standard instruction for the general public in the official label.

Q: Is Loratin addictive or habit-forming?

The drug is a second-generation compound that has a high selectivity for receptors outside the brain. It is noted that the drug is not associated with the central nervous system depressant effects linked to older antihistamines.

How should Loratin be stored and disposed of?

Storage Conditions and Environment

Loratadine tablets must be stored at Controlled Room Temperature, which is generally between 20 C and 25 C (68 F and 77 F). The medication must be kept protected from excessive moisture and light, as specified in the official labeling. Loratadine oral solution (syrup) has a required storage range of 2 C to 25 C (36 F to 77 F). The product must be stored in its original container, and the blister or seal integrity should be intact before use.

Safety and Disposal Requirements

Loratadine must be kept out of reach of children as a mandatory safety requirement stated in the labeling. Regarding disposal, official regulatory guidance requires that any unused or expired product be disposed of in accordance with local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Loratin found in:

A-Z Index: